News

Follow the latest news on Bioqube Ventures, the Bioqube Factory Fund and our portfolio companies here.

26/05/2022

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Awarded grant funding from Johnson & Johnson Innovation and one year of JLABS residency Functional genomics technology focused on the uncharted non-coding regions across the whole human genome Identification of 3D genetic interactions that are disease-associated to revolutionise target and biomarker identification Unique GenLink3DTM platform opens new opportunities for multiOMICs data integration in patient samples […]

30/11/2021

Lonza and Bioqube Ventures Sign a Framework Agreement for the Future Development and Manufacture of Biologics and Small Molecules for Bioqube’s Portfolio Companies

The five-year services agreement provides for the development and manufacturing of biologics and small molecules for portfolio companies of Bioqube Ventures The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies, Lonza to support Bioqube Ventures with investment de-risking and providing development and manufacturing of drug substance and drug product […]

04/11/2021

Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing

SAN DIEGO, November 4, 2021 – Primmune Therapeutics today announced that it has received $8.4 million in a second tranche of the Company’s Series A financing. The total proceeds for the equity raised in the Series A was $31.4 million. These funds will be used to support the further clinical development of PRTX007 as a […]

02/11/2021

Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™

SAN DIEGO, November 2, 2021 – Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including SARS-CoV-2, and cancer. This double blind, placebo-controlled Phase 1 study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics […]

26/10/2021

Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers

LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has completed a €40M ($46.4M) Series A financing. The Series A was co-led by […]

16/08/2021

Anavo Therapeutics to Establish R&D Hub in World-Leading Cancer Research Cluster

Leiden, The Netherlands, and Heidelberg, Germany, August 16, 2021 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced that the company has partnered with BioLabs Global, a developer and operator of premium co-working laboratories in the U.S. and Europe, to establish its R&D center as one of […]

24/06/2021

Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology

Karl-Heinz Altmann, Andrew Mortlock and Gregg Siegal to join Anavo’s SAB Leiden, The Netherlands, June 24, 2021 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced three key appointments to its Scientific Advisory Board in the persons of Karl-Heinz Altmann, currently Full Professor of Pharmaceutical Sciences […]

22/04/2021

Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

09/03/2021

Primmune Therapeutics Strengthens Leadership Team with Key Appointments

SAN DIEGO, February 5, 2021 – Today, Primmune Therapeutics announced the appointment of Rich Daniels as Chief Operating Officer, Scott Zook as Senior Vice President, Global Manufacturing and Randy Adams as Senior Advisor, Commercial Development. “The appointments of Rich, Scott and Randy to the team build on the recent close of our Series A financing to support the […]

12/01/2021

Primmune Therapeutics Announces Close of Series A Financing

SAN DIEGO, January 12, 2021 – Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of the Series A financing raise to $31.4 million. These funds will be used to support the development of PRTX007, […]

24/09/2020

Bioqube Ventures welcomes two seasoned professionals

Brussels/Hasselt, Belgium – 24th September 2020 – Bioqube Ventures, a European life sciences venture capital firm, today announces that Tom Heyman joins Bioqube Ventures as Operating Partner and Peter Verhaeghe will chair the LP and Advisory Committee of the Bioqube Factory Fund I. Bolstering the team with industry veterans Tom Heyman and Peter Verhaeghe will […]

10/06/2020

Bioqube Ventures launches Bioqube Factory Fund I

Bioqube Ventures announces today the first closing of Bioqube Factory Fund I, a new early stage venture capital fund focused on the development of therapeutic assets and technology platforms in Europe.